The findings on DBC1, H4K16Ac, and H3K9Ac also suggested that SIRT1 acted as an oncogene and thus might be a potential target for HDAC inhibitor treatment in gastric cancer patients. This evidence concerns the gene HDAC9 and gastric cancer.